BR100 Increased By (0.11%)
BR30 Increased By (0.49%)
KSE100 Increased By (0.31%)
KSE30 Increased By (0.33%)
AGHA 6.39 Increased By ▲ 0.07 (1.11%)
BECO 4.35 Increased By ▲ 0.08 (1.87%)
BML 62.71 Increased By ▲ 0.26 (0.42%)
BOP 31.40 Increased By ▲ 0.17 (0.54%)
CNERGY 11.74 Increased By ▲ 0.15 (1.29%)
CSIL 5.94 Increased By ▲ 0.22 (3.85%)
FCCL 61.65 Increased By ▲ 0.11 (0.18%)
FFL 14.88 Decreased By ▼ -0.14 (-0.93%)
FNEL 1.25 Increased By ▲ 0.02 (1.63%)
KEL 6.33 Increased By ▲ 0.07 (1.12%)
KOSM 5.89 Increased By ▲ 0.33 (5.94%)
LOTCHEM 24.70 Increased By ▲ 0.02 (0.08%)
MLCF 103.95 Decreased By ▼ -0.13 (-0.12%)
NBP 173.05 Decreased By ▼ -2.23 (-1.27%)
NCPL 51.89 Decreased By ▼ -0.88 (-1.67%)
NPL 54.10 Decreased By ▼ -0.02 (-0.04%)
OGDC 316.37 Increased By ▲ 2.98 (0.95%)
PACE 9.26 Increased By ▲ 0.06 (0.65%)
PAEL 35.58 Decreased By ▼ -0.22 (-0.61%)
PIBTL 13.67 Increased By ▲ 0.20 (1.48%)
PPL 226.75 Increased By ▲ 4.94 (2.23%)
PRL 80.12 Increased By ▲ 1.04 (1.32%)
PTC 46.55 Decreased By ▼ -0.30 (-0.64%)
SSGC 23.83 Decreased By ▼ -0.04 (-0.17%)
TBL 9.23 Decreased By ▼ -0.08 (-0.86%)
TELE 7.60 Increased By ▲ 0.21 (2.84%)
TPL 24.55 Decreased By ▼ -0.56 (-2.23%)
TPLP 13.05 Increased By ▲ 0.54 (4.32%)
TREET 26.00 Decreased By ▼ -0.25 (-0.95%)
TRG 53.36 Decreased By ▼ -0.08 (-0.15%)
World

In England, William Shakespeare receives a COVID-19 vaccine

  • He was one of the first people to receive the newly approved COVID-19 vaccine outside a clinical trial on Tuesday.
Published Updated
By

William Shakespeare from Warwickshire in England was one of the first people to receive the newly approved COVID-19 vaccine outside a clinical trial on Tuesday.

The 81-year-old had the injection at University Hospital Coventry on Tuesday, 20 miles from Stratford-Upon-Avon, the birthplace of his namesake, England’s greatest dramatist and poet.

Shakespeare’s shot inspired Twitter users, who joked “The Taming of the Flu”, “The Two Gentlemen of Corona”. Some asked if Margaret Keenan was patient 1A, then was Shakespeare “Patient 2B or not 2B?”.

Comments

Comments are closed for this article.